All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.
Usmarapride (SUVN-D4010) free base is a potent, selective, orally active and brain penetrant 5-HT4 receptor partial agonist (EC50=44 nM). Usmarapride (SUVN-D4010) free base can be used for the research of cognitive deficits associated with Alzheimer's disease.
| Molecular Weight | 383.49 |
| Formula | C21H29N5O2 |
| CAS Number | 1428862-32-1 |
| Form | Solid |
| Solubility (25°C) | DMSO ≥ 100 mg/mL |
| Storage | Powder -20°C |
| Related 5-HT Receptor Products |
|---|
| Granisetron hydrochloride
Granisetron hydrochloride is a potent and selective 5-HT3 receptor antagonist that possesses potent antiemetic activity. |
| Sumatriptan succinate
Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for the research of migraine headache. |
| Vortioxetine hydrobromide
Vortioxetine hydrobromide (Lu AA21004) is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist and a 5-HT transporter (5-HTT) inhibitor in vitro. |
| Prucalopride
Prucalopride is a potent, selective and specific serotonin 5-HT4 receptor agonist with enterokinetic properties. |
| (1S-cis)-Milnacipran Hydrochloride
(1S-cis)-Milnacipran hydrochloride is a selective norepinephrine and serotonin reuptake inhibitor approved for the management of fibromyalgia. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
